Correlation of Mean Corpuscular Volume with Clinical Features and Prognosis of Patients with Treatment-Related Acute Myeloid Leukemia
ObjectiveTo analyze the correlation of mean corpuscular volume (MCV) with clinical features and the prognosis of patients with treatment-related acute myeloid leukemia (t-AML). MethodsThe clinical and laboratory data of 41 patients with t-AML were retrospectively analyzed. The patients were divided...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-05-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1214 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ObjectiveTo analyze the correlation of mean corpuscular volume (MCV) with clinical features and the prognosis of patients with treatment-related acute myeloid leukemia (t-AML). MethodsThe clinical and laboratory data of 41 patients with t-AML were retrospectively analyzed. The patients were divided into LMCV and HMCV groups. Spearman’s rank correlation was used for correlation analysis, and a survival curve was drawn via Kaplan-Meier method. Log-rank test was used for comparison between groups, and Cox proportional risk regression model was used for multivariate analysis. ResultsThe treatment history of G-CSF was positively correlated with the MCV of patients with t-AML (correlation coefficient r=0.325, P<0.05). The amount of RBC and HGB in the peripheral blood of patients and the percentage of PML-RARa positive in the LMCV group were significantly higher than those in the HMCV group, and the percentages of the expression levels of lymphoid antigen CD7 and CD56 were significantly lower than those in the HMCV group (P<0.05). The therapeutic effect, OS, and RFS of the LMCV group were better than those of the HMCV group (P<0.05). Failure to reach CR was an independent risk factor for OS of patients with t-AML (HR=0.053, P=0.002), and MCV≥98.9 fl was an adverse factor for OS and RFS of patients with t-AML (P<0.1) but not an independent risk factor (P>0.05). ConclusionPatients with t-AML with different levels of MCV have different clinical characteristics, and patients with high MCV have poor therapeutic effect and prognosis. |
|---|---|
| ISSN: | 1000-8578 |